The MIT Corporation - the Institute's board of trustees - elected nine full-term members, who will each serve for five years; two partial-term members;.
Credits: Courtesy of the Office of the Corporation
Previous image
Next image
The MIT Corporation the Institute’s board of trustees elected nine full-term members, who will each serve for five years; two partial-term members; and three life members, during its quarterly meeting today. Corporation Chair Diane Greene SM ’78 announced the election results; all positions are effective July 1.
The nine full-term members are: Lindsay Androski ’98; Eran Broshy ’79; Ashton Carter; Fiona Chen ’21; Kevin Churchwell ’83; Grace Colón PhD ’95; Diane Hoskins ’79; Pearl Huang ’80; and Ray Rothrock SM ’78. The two partial-term members are: Michael “Mick” Mountz ’87; and Mark Wrighton. The three life members are: Patricia Callahan ’75, SM ’77; Alan Levanthal; and Kenneth Wang ’71.
Juvenescence Limited: Juvenescence Appoints Dr. Grazia Piizzi as Chief Scientific Officer
Dr. Grazia Piizzi, PhD, has joined its Executive Management Team as Chief Scientific Officer.
Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the ?rst place. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors.
Dr. Piizzi has more than 15 years of experience in the global pharmaceutical and biotech industry. Most recently, she was the SVP of Small Molecules R&D and Head of Inflammation at a Flagship Pioneering startup, Cygnal Therapeutics, decoding the links between peripheral neurons and diseases (2019-2021). Previously, she held the position of Executive Di
BioSpace Movers & Shakers, March 19 biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK and PERTH, Australia, March 17, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering, a leading-edge innovation organization that conceives, creates and develops first-in-category life science companies, and the former Chief Medical Officer of Merck, one of the world s leading global biopharmaceutical companies.
Dr. Rosenblatt brings over four decades of visionary leadership experience across biopharmaceutical companies and academic institutions, and as a practicing physician. In his current role at Flagship, he has helped launch several renowned biotechnology companies in the Flagship ecosystem, including providing counsel on clinical development strategies a